474P Evaluation of gelatinase-responsive copolymeric nanoparticles targeting PD-1 and TGF-β pathways for treating immune-resistant tumor

Abstract

Immune checkpoint inhibitors have revolutionized cancer treatment but only a fraction of patients actually benefitted since the development of resistance. Simultaneously targeting PD-1 and TGFβ is prompted to be a favorable strategy to reverse the phenomenon but the hydrophobicity of TGFβ inhibitors and latent drug-related adverse events restrained the utility. To circumvent this hindrance, we construct an enzymatically responsive nanoscale drug delivery system on the basis of our previous work and loaded it with αPD-1 antibody and TGFβ inhibitor, referring to as GPNPs.